The long-term immunogenicity and protection provided by a plasma-derived hepatitis B vaccine (Heptavax B) was determined in a cohort of susceptible persons immunized in 1981. In this study 1581 susceptible persons were immunized with the recommended three-dose regimen of hepatitis B vaccine. After 7 years, 74% of vaccinees retained antibody to hepatitis B surface antigen (anti-HBs) levels of 10 mlU/mL or more. Anti-HBs levels at 7 years varied inversely with age and directly with the level of anti-HBs attained 1 year after the first dose. During the 7 years after the first dose of vaccine, five vaccine responders and three other persons developed antibody to hepatitis B core antigen and their level of anti-HBs increased. None developed detectable hepatitis B surface antigen or clinical hepatitis. This update of an ongoing study continues to suggest that the risk of hepatitis B virus infection to most persons with an initial anti-HBs response to hepatitis B virus vaccine of 10 mlU/mL or greater is low, regardless of the initial antibody level.
(Arch Intern Med. 1991;151:1634-1636)
Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection Provided by Hepatitis B Vaccine in a Yupik Eskimo Population: Seven-Year Results. Arch Intern Med. 1991;151(8):1634–1636. doi:10.1001/archinte.1991.00400080118023
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: